Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11751691 | 0.89 | EPHX1 (0.65) | EPHX1GAANAAASMN1; SMN2HDAC1 | |
| SCHEMBL10879403 | 0.89 | EPHX1 (0.65) | EPHX1GAANAAATPSAB1TPSD1 | |
| SCHEMBL10817282 | 0.87 | EPHX1 (0.71) | EPHX1GAANAAASMN1; SMN2HDAC4 | |
| SCHEMBL24091968 | 0.85 | EPHX1 (0.45) | EPHX1GAATDP1TPSAB1TPSD1 | |
| SCHEMBL8429028 | 0.84 | EPHX1 (0.59) | EPHX1GAANAAASMN1; SMN2TPSAB1 | |
| SCHEMBL22136179 | 0.84 | EPHX1 (0.69) | EPHX1GAANAAA | |
| SCHEMBL22224323 | 0.84 | EPHX1 (0.59) | EPHX1GAANAAASMN1; SMN2TPSAB1 | |
| SCHEMBL2801495 | 0.84 | EPHX1 (0.69) | EPHX1GAANAAA | |
| SCHEMBL24507877 | 0.83 | EPHX1 (0.56) | EPHX1GAASMN1; SMN2TPSAB1TPSD1 | |
| SCHEMBL12991745 | 0.83 | EPHX1 (0.67) | EPHX1GAANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | EPHX1 369/4885GAA 782/4885NAAA 2999/4885 |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | EPHX1 369/4885GAA 782/4885NAAA 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.